An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014

• 来源期刊: 药学学报（英文版）
• 关键词: Erik De Clercq Antiviral drug Poly(I)·poly(C) Polyacrylic acid Interferon Reverse transcriptase Suramin Valaciclovir Brivudin Stavudine Tenofovir disoproxil fumarate (TDF) Truvada(R) Atripla(R) Complera(R)/Eviplera(R) Stribild(R) FV-100 Mozobil(R) Tenofo
• 年，卷（期）: 2015,（6）
• 页码范围: 520-543
• 页数: 24页
• 语种: 中文

摘要

Ⅰ.How it started I entered the Rega Institute for Medical Research in August 1964, as a medical student, to start working under the guidance of Prof Piet De Somer, then professor of microbiology at the Leuven School of Medicine.When I graduated as medical doctor (MD) in 1966, I hesitated between a clinical career in Internal Medicine or a scientific career in experimental research, the latter under the tutorship of Prof De Somer who persuaded me to work on interferon (inducers).The discovery of the interferon-inducing capacity of doublestranded RNAs, such as poly(1)·poly(C), by Maurice Hilleman's group at Merck in 1967 would prove of key importancein my decision to engage in interferon research.